JP2023528002A5 - - Google Patents

Info

Publication number
JP2023528002A5
JP2023528002A5 JP2022572706A JP2022572706A JP2023528002A5 JP 2023528002 A5 JP2023528002 A5 JP 2023528002A5 JP 2022572706 A JP2022572706 A JP 2022572706A JP 2022572706 A JP2022572706 A JP 2022572706A JP 2023528002 A5 JP2023528002 A5 JP 2023528002A5
Authority
JP
Japan
Prior art keywords
bispecific molecule
surface antigen
binding
optionally
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022572706A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528002A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/034526 external-priority patent/WO2021243028A1/en
Publication of JP2023528002A publication Critical patent/JP2023528002A/ja
Publication of JP2023528002A5 publication Critical patent/JP2023528002A5/ja
Pending legal-status Critical Current

Links

JP2022572706A 2020-05-27 2021-05-27 T細胞を選択的に調節するための二重特異性分子 Pending JP2023528002A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063030714P 2020-05-27 2020-05-27
US63/030,714 2020-05-27
PCT/US2021/034526 WO2021243028A1 (en) 2020-05-27 2021-05-27 Bispecific molecules for selectively modulating t cells

Publications (2)

Publication Number Publication Date
JP2023528002A JP2023528002A (ja) 2023-07-03
JP2023528002A5 true JP2023528002A5 (cg-RX-API-DMAC7.html) 2024-05-31

Family

ID=78722762

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022572706A Pending JP2023528002A (ja) 2020-05-27 2021-05-27 T細胞を選択的に調節するための二重特異性分子

Country Status (7)

Country Link
US (1) US20230203157A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157354A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023528002A (cg-RX-API-DMAC7.html)
KR (1) KR20230029611A (cg-RX-API-DMAC7.html)
AU (1) AU2021279028A1 (cg-RX-API-DMAC7.html)
CA (1) CA3177550A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021243028A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200037250A (ko) 2017-07-06 2020-04-08 메뤼스 엔.페. 세포에 의해 발현되는 생물학적 활성을 조절하는 항체
PE20241732A1 (es) 2021-03-31 2024-08-19 Merus Nv Dominios de union a pd-1 novedosos
US12559576B2 (en) 2021-11-11 2026-02-24 Regeneron Pharmaceuticals, Inc. CD20-PD1 binding molecules and methods of use thereof
WO2024156006A2 (en) * 2023-01-20 2024-07-25 New York University Targeting mhc-i antigen presentation modulators for immunotherapy for cancer and autoimmune disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009380A1 (en) * 1994-09-23 1996-03-28 The University Of British Columbia Method of enhancing expression of mhc class i molecules bearing endogenous peptides
AU2009298131B2 (en) * 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
UA128469C2 (uk) * 2015-10-08 2024-07-24 Макродженікс, Інк. Спосіб лікування в7-н3-експресуючого раку
CN108699158B (zh) * 2016-03-08 2022-06-03 依奈特制药公司 Siglec中和抗体
BR112019018915A2 (pt) * 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
CN109575139A (zh) * 2017-09-29 2019-04-05 上海药明生物技术有限公司 针对表皮生长因子受体和程序性死亡受体的双特异抗体
WO2019153200A1 (zh) * 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
WO2020018715A1 (en) * 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof

Similar Documents

Publication Publication Date Title
JP7781243B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
RU2644686C2 (ru) Идентификация опухолеассоциированных антигенов для диагностики и терапии
KR102363742B1 (ko) Cd19에 대한 인간화 항원-결합 도메인 및 사용 방법
CN112969476B (zh) 多特异性蛋白分子
WO2020114478A1 (zh) Cd3抗体及其药物用途
JP2020504095A (ja) 抗PD−L1抗体との組み合わせのための抗Tim−3抗体
JP2019509055A (ja) 多特異性免疫調節抗原結合構築物
JP2021518133A5 (cg-RX-API-DMAC7.html)
US20230203157A1 (en) Bispecific molecules for selectively modulating t cells
WO2006075784A1 (ja) 抗α9インテグリン抗体とその用途
JP2018532427A (ja) 抗cd95l抗体
JP5566374B2 (ja) 形質細胞の腫瘍性増殖をきたす疾患の治療薬
CN115894702A (zh) 一种b7h3/pdl1双特异性抗体及其药物组合物及应用
CN120718148A (zh) 一种抗cd38纳米抗体及其制备方法与应用
CN110615841B (zh) 抗人cd47单克隆抗体及其应用
Iizuka et al. Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy
CN109593135B (zh) 抗人pd-l1单克隆抗体及其应用
RU2802272C2 (ru) Антитело к cd3 и его фармацевтическое применение
HK40103404A (en) Process for producing personalized cancer immunotherapy
HK40088602A (en) Antibodies binding tnfr2 and uses thereof
EA052990B1 (ru) Химерный антигенный рецептор антител к hk2 (car)
HK40051452B (en) Cd3 antibody and pharmaceutical use thereof
KR20190107967A (ko) 한국인 위암 연관 유전자 단클론 항체 및 이의 제조방법
HK1168609A (en) Identification of tumor-associated antigens for diagnosis and therapy
HK1168610A (en) Identification of tumor-associated antigens for diagnosis and therapy